Abstract 1776
Background
Mobile phones and tablets currently represent a significant presence in people’s everyday lives. They enable access to different information and services independent of current place and time. Such widespread connectivity offers significant potential in different app areas including health care. Advancements in mobile technology allow innovative data collection techniques such as measuring time use for the purpose of improving health behavior change interventions.
Methods
The aim of this study is to examine the usage rates of healthcare users and the health content of applications. A total of 707 mobile app were retrieved through a Google and App store for app published between January to April 2019. In this context, all applications were scanned using "cancer", "oncology", and "breast cancer" keywords on these stores. Repetitive applications were removed and research data was obtained. The applications were evaluated by considering their contents, developers and download numbers.
Results
In the Google play store, under the training title of 268 applications, it was found that 76 applications were used to maintain the treatment scheme and plan, and 12 were used for communication purposes. In the app store, it was determined that 235 applications were used for education, 102 for treatment plan and order, and 14 for communication purposes. Educational applications were used for journal, congress, student information, cancer guidelines and patient information. Drug management for treatment regimen and plan was determined to be related to radiological imaging, diet follow-up, symptoms, and nutrition. It was seen that communication applications were used for both patient-patient and physician-patient interaction. It was found that only 8% of the existing applications that the majority of the application developers did not have a healthcare staff established a health care staff.
Conclusions
It can be said that health personnel develop their own systems and provide accurate information to patients through these systems. With the advancement of health technologies, healthy results can be obtained in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract